DNA dendrimer-based nanocarriers for targeted Co-delivery and controlled release of multiple chemotherapeutic drugs. [PDF]
RSC AdvTian Y, Sun M, Song R, Yang Z, Zhang H.
europepmc +1 more source
Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis
Muscle &Nerve, Volume 71, Issue 6, Page 1006-1015, June 2025.ABSTRACT Introduction/Aims Tofersen is approved for the treatment of amyotrophic lateral sclerosis (ALS) due to superoxide dismutase 1 mutations (SOD1‐ALS). Here we report serious neurologic adverse events (AEs) that occurred in the tofersen clinical trials in people with SOD1‐ALS.
Alexandra Lovett +17 more
wiley +1 more source
DragonRNA: Generality of DNA-primed RNA-extension activities by DNA-directed RNA polymerases. [PDF]
Nucleic Acids ResGreenwald E +7 more
europepmc +1 more source
Differential Protein Precipitation-Based GalNAc-siRNA Sample Preparation with LC/MS Method Development Workflow in Plasma. [PDF]
Anal ChemKim Y +4 more
europepmc +1 more source
A pH-Responsive Dendritic-DNA-Based Nanohydrogel for Dual Drug Delivery. [PDF]
BiomoleculesZhao J, Wu J, Fan Y, Yu C, Yu L, Shao F.
europepmc +1 more source
Introduction to the themed collection in honour of Professor Christian Leumann. [PDF]
RSC Med ChemHollenstein M, Stulz E.
europepmc +1 more source
Widespread tissue delivery of antagomiRs via intramuscular administration. [PDF]
Mol Ther Methods Clin DevMessios C, Koutsoulidou A, Phylactou LA.
europepmc +1 more source
Pathogenetic therapeutic approaches for endocrine diseases based on antisense oligonucleotides and RNA-interference. [PDF]
Front Endocrinol (Lausanne)Golounina O +6 more
europepmc +1 more source
MALT1: The Dual Domains Drive Resistance to Immune Checkpoint Inhibitors
MedComm – Future Medicine, Volume 4, Issue 2, June 2025.
Haoze Xie, Jie Zhang, Yicheng Chen
wiley +1 more source